Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACE-86225106 in advanced solid tumors
NCT06380660Phase 2Active, not recruiting
- Sponsor
- Acerand Therapeutics
- Start
- Mar 2024
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ACE-86225106 in solid tumor, ovarian cancer, breast cancer, prostate cancer (PCa), sponsored by Acerand Therapeutics. Started Mar 2024; status: active, not recruiting.
02
Drugs
ACE-86225106
03
Conditions
solid tumorovarian cancerbreast cancerprostate cancer (PCa)
Beyond the preview
Go deeper on NCT06380660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06380660.